NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital hits record $1.2 billion (€1 billion) close for Jeito II Fund to drive breakthrough therapeutic innovation for patients
This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital co-leads EUR 65 million (USD 71 million) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases
Jeito Capital co-leads oversubscribed financing Corteria, a late preclinical stage company, is...
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for Claudin-1 in cancer & fibrosis
Funds will support the Phase I/II clinical development of Alentis’ two first-in-class...
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
Noema Pharma's clinical-stage assets and diversified pipeline hold significant potential in...
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing
The Series C extension round will accelerate clinical development, manufacturing scale-up and...
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
Deal validates Jeito’s unique investment model of selecting high-quality assets developed by...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.